Please ensure Javascript is enabled for purposes of website accessibility

Best Stock for 2009: Pfizer

By Brian Orelli, PhD - Updated Apr 5, 2017 at 7:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's cheap enough to be a bull again.

Which stocks are looking fine in ’09? Discover all our Foolish ideas for The Best Stocks for 2009.

It pains me to use the words Pfizer (NYSE:PFE) and "best" in the same title. The company has languished for so long -- and for good reason.

But it's time to sing a different tune about Pfizer. The Lipitor patent cliff is still staring the company in the face, but the languishing stock price has made the company so much more attractive; it could see a breakout in 2009.

An OK pipeline
When a company is raking in nearly $49 billion in yearly revenue, it takes a lot of drugs to move the top line. Fortunately, Pfizer has a decent pipeline, with 15 drugs being tested in 24 different indications in phase 3 trials.

Factoring in failures, those drugs probably aren't going to be enough to replace sales of Lipitor and the other drugs that are going off patent in the coming years, but they don't really have to. Pfizer is trading at such a discount to its usual multiples -- price to earnings, price to free cash flow, pretty much anything else you can think of -- that the company can afford to take the hit to revenue and not look overly expensive.

And with recent cutbacks in its workforce, the hit to the bottom line shouldn't be nearly as extreme as the blow to revenue when Pfizer loses Lipitor. Companies can't cut their way to earnings growth forever, but a leaner, meaner Pfizer should be able to handle the loss a lot easier than the bulky one that could hide the fat with a blockbuster drug growing year after year.

A mountain of cash
Pfizer's sitting on a pile of cash that's 26 billion dollars high. That's considerably more than its competitors:


Cash and Short-Term Investments (billions)



Johnson & Johnson (NYSE:JNJ)


Wyeth (NYSE:WYE)


GlaxoSmithKline (NYSE:GSK)




Source: Capital IQ, a division of Standard & Poor's. As of the quarter ending September 2008.

I've certainly been part of the do-something-already bandwagon that's been parading around Pfizer for many years, but clearly waiting has worked. Many drug companies are available at dirt-cheap prices and, as Johnson & Johnson has already shown, shrewd use of cash can result in picking up companies for deep discounts.

Hopefully, any acquisitions Pfizer makes in the coming years will help to supplement its pipeline or even contribute revenues immediately.

Getting paid to wait
Even if there isn't a catalyst in 2009 to really make the stock take off, investors need not stay away. With the dividend intact for another year, Pfizer's paying its investors quite well to just stay put.


Dividend Yield



Merck (NYSE:MRK)


Bristol-Myers Squibb (NYSE:BMY)


Eli Lilly (NYSE:LLY)


Source: Motley Fool CAPS.

While I guess it's possible that Pfizer could drop more, it seems likely that it'll trade sideways during the year. The 7%-plus payout should be enough to reward investors for waiting.

What more could a Fool ask for?
For 2009 to look nothing like 2008, for one thing.

Fools need to remember that investing is a long-term endeavor. Pfizer's overall picture isn't likely to change that much in 2009, but that doesn't mean that now isn't a good time to invest. Investors are a fickle bunch, and determining when Pfizer might take off is difficult.

Will a decent pipeline, a mountain of cash, and a fat dividend be enough to give investors a nice return in 2009? Cast your vote by marking Pfizer an outperform or underperform at Motley Fool CAPS, and join more than 120,000 other Fools interested in making next year a profitable one.

Pfizer, Eli Lilly, Johnson & Johnson, and GlaxoSmithKline are Motley Fool Income Investor selections. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of Pfizer, which is a Motley Fool Inside Value pick. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$49.95 (0.34%) $0.17
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$89.19 (-0.37%) $0.33
Eli Lilly and Company Stock Quote
Eli Lilly and Company
$304.61 (0.53%) $1.59
Johnson & Johnson Stock Quote
Johnson & Johnson
$170.67 (0.29%) $0.49
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$74.86 (-0.13%) $0.10
GSK Stock Quote
$38.30 (-4.32%) $-1.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.